Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces Filing of Purported Class Action Lawsuits
Date:7/23/2009

DETROIT, July 23 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced that on July 17, 2009 and July 23, 2009, two purported federal securities class action lawsuits were filed in the United States District Court for the Eastern District of Michigan against the Company and certain of its executive officers. The defendants have not yet been served with either suit. Plaintiffs purport to represent the class of persons who purchased or otherwise acquired the common stock of the Company generally between May 29, 2008 and June 25, 2009. Plaintiffs generally allege that during this time period defendants violated federal securities laws, primarily related to public statements on FDA compliance. The Company believes the plaintiffs' allegations are without merit and intends to vigorously contest the actions.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation
2. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
3. Caraco Pharmaceutical Laboratories, Ltd. Announces an Indefinite Reduction in its Workforce
4. Caraco Pharmaceutical Laboratories, Ltd. Updates on Financial Position
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action
6. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection
7. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Roxicodone(R) Tablets
8. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces a Nationwide Voluntary Recall of All Lots of Digoxin Tablets Due to Size Variability
10. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009
11. Caraco Pharmaceutical Laboratories, Ltd. to Announce Third Quarter of Fiscal Year 2009 Results on January 29, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... FOR INFORMATION: ... AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference is the ... perioperative nurses in attendance to study the latest evidence-based recommendations and resources ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown ... to reduce the frequency and level of relapse. , At the ... and Purpose,” will explore the critical tasks of the recovery phase and beyond ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Today, the Whole-Food ... announced that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, ... Network. , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... announce the addition of micro-needling services in their Napa Valley office. The technique ... of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only ...
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 Aethlon ... Jim Joyce , Chairman and CEO, will be presenting at ... New York, NY at 2:15 p.m. ... participate in an Immunotherapy Panel discussion taking place at 3:15 ... available for replay approximately one hour after the conclusion of ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)... 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... announced underwritten secondary offering of 11,027,558 shares of its ... affiliates of Blackstone and Goldman Sachs.  The shares are ... of $96.45 per share. The selling stockholders will receive ... Biomet nor any of its directors, officers or other ...
Breaking Medicine Technology: